John Dixon ANZOS Annual Scientific Meeting 2021

Abstracts this author is presenting:

• Semaglutide 2.4 mg and intensive behavioural therapy in subjects with overweight or obesity (STEP 3) — Concurrent Oral Abstracts 2 - Clinical